202
Views
8
CrossRef citations to date
0
Altmetric
Original Article

Primary Pleural Epithelioid Mesothelioma of Clear Cell Type: A Case Report and Review of Current Literature

, MD, , MD, PhD & , MD, PhD
Pages 267-270 | Received 13 Jul 2011, Accepted 15 Jul 2011, Published online: 06 Oct 2011

REFERENCES

  • Hammar SP. Macroscopic, histologic, histochemical, immunohistochemical, and ultrastructural features of mesothelioma. Ultrastruct Pathol. 2006;30:3–17.
  • Ordonez NG, Myhre M, Mackay B. Clear cell mesothelioma. Ultrastruct Pathol. 1996;20:331–336.
  • Cavazza A, Pasquinelli G, Agostini L, Leslie KO, Colby TV. Foamy cell mesothelioma. Histopathology. 2002;41:369–371.
  • Dessy E, Falleni M, Braidotti P, Del CB, Panigalli T, Pietra GG. Unusual clear cell variant of epithelioid mesothelioma. Arch Pathol Lab Med. 2001;125:1588–1590.
  • Ordonez NG, Mackay B. Glycogen-rich mesothelioma. Ultrastruct Pathol. 1999;23:401–406.
  • Ordonez NG. Mesothelioma with clear cell features: an ultrastructural and immunohistochemical study of 20 cases. Hum Pathol. 2005;36:465–473.
  • Ordonez NG. Clear cell mesothelioma presenting as an incarcerated abdominal hernia. Virchows Arch. 2005;447:823–827.
  • Roggli VL, Sharma A, Butnor KJ, Sporn T, Vollmer RT. Malignant mesothelioma and occupational exposure to asbestos: a clinicopathological correlation of 1445 cases. Ultrastruct Pathol. 2002;26:55–65.
  • Davidson B. New diagnostic and molecular characteristics of malignant mesothelioma. Ultrastruct Pathol. 2008;32:227–240.
  • Ordonez NG. What are the current best immunohistochemical markers for the diagnosis of epithelioid mesothelioma? A review and update. Hum Pathol. 2007;38:1–16.
  • Kushitani K, Takeshima Y, Amatya VJ, Furonaka O, Sakatani A, Inai K. Immunohistochemical marker panels for distinguishing between epithelioid mesothelioma and lung adenocarcinoma. Pathol Int. 2007;57:190–199.
  • Chenard-Neu MP, Kabou A, Mechine A, Brolly F, Orion B, Bellocq JP. [Immunohistochemistry in the differential diagnosis of mesothelioma and adenocarcinoma: evaluation of 5 new antibodies and 6 traditional antibodies]. Ann Pathol. 1998;18:460–465.
  • Fetsch PA, Abati A, Hijazi YM. Utility of the antibodies CA 19-9, HBME-1, and thrombomodulin in the diagnosis of malignant mesothelioma and adenocarcinoma in cytology. Cancer. 25-4-1998;84:101–108.
  • Ordonez NG. The diagnostic utility of immunohistochemistry in distinguishing between mesothelioma and renal cell carcinoma: a comparative study. Hum Pathol. 2004;35:697–710.
  • Joshi A, McAndrew N, Birdsall S, Attanoos RL. Clear cell sarcoma mimicking malignant pleural mesothelioma. Histopathology. 2008;53:359–361.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.